Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy
Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC d...
Ausführliche Beschreibung
Gespeichert in:
| Autor*in: |
Sakr, Marwa Ahmed [verfasserIn] Mohamed, Khaled Abdel Hamid [verfasserIn] Hussein, Ahmed Mohamed [verfasserIn] Fouad, Mohamed Hassan [verfasserIn] Allam, Ahmed Samir [verfasserIn] Safwat, Eslam [verfasserIn] |
|---|
| Format: |
E-Artikel |
|---|---|
| Sprache: |
Englisch |
| Erschienen: |
2021 |
|---|
| Schlagwörter: |
|---|
| Übergeordnetes Werk: |
Enthalten in: Egyptian liver journal - [London] : SpringerOpen, 2011, 11(2021), 1 vom: 27. März |
|---|---|
| Übergeordnetes Werk: |
volume:11 ; year:2021 ; number:1 ; day:27 ; month:03 |
| Links: |
|---|
| DOI / URN: |
10.1186/s43066-021-00090-y |
|---|
| Katalog-ID: |
SPR04364015X |
|---|
| LEADER | 01000naa a22002652 4500 | ||
|---|---|---|---|
| 001 | SPR04364015X | ||
| 003 | DE-627 | ||
| 005 | 20210328064719.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 210328s2021 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.1186/s43066-021-00090-y |2 doi | |
| 035 | |a (DE-627)SPR04364015X | ||
| 035 | |a (DE-599)SPRs43066-021-00090-y-e | ||
| 035 | |a (SPR)s43066-021-00090-y-e | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Sakr, Marwa Ahmed |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| 264 | 1 | |c 2021 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a Computermedien |b c |2 rdamedia | ||
| 338 | |a Online-Ressource |b cr |2 rdacarrier | ||
| 520 | |a Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. | ||
| 650 | 4 | |a HCC |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Soluble CD163 |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Transarterial chemoembolization |7 (dpeaa)DE-He213 | |
| 650 | 4 | |a Radiofrequency ablation |7 (dpeaa)DE-He213 | |
| 700 | 1 | |a Mohamed, Khaled Abdel Hamid |e verfasserin |4 aut | |
| 700 | 1 | |a Hussein, Ahmed Mohamed |e verfasserin |4 aut | |
| 700 | 1 | |a Fouad, Mohamed Hassan |e verfasserin |4 aut | |
| 700 | 1 | |a Allam, Ahmed Samir |e verfasserin |4 aut | |
| 700 | 1 | |a Safwat, Eslam |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Egyptian liver journal |d [London] : SpringerOpen, 2011 |g 11(2021), 1 vom: 27. März |w (DE-627)1733559663 |w (DE-600)3038187-3 |x 2090-6226 |7 nnns |
| 773 | 1 | 8 | |g volume:11 |g year:2021 |g number:1 |g day:27 |g month:03 |
| 856 | 4 | 0 | |u https://dx.doi.org/10.1186/s43066-021-00090-y |z kostenfrei |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a SYSFLAG_A | ||
| 912 | |a GBV_SPRINGER | ||
| 951 | |a AR | ||
| 952 | |d 11 |j 2021 |e 1 |b 27 |c 03 | ||
| author_variant |
m a s ma mas k a h m kah kahm a m h am amh m h f mh mhf a s a as asa e s es |
|---|---|
| matchkey_str |
article:20906226:2021----::igotcnponsivlefeuslbed6icrhtcainsiheaiiciurltdeaoellrac |
| hierarchy_sort_str |
2021 |
| publishDate |
2021 |
| allfields |
10.1186/s43066-021-00090-y doi (DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e DE-627 ger DE-627 rakwb eng Sakr, Marwa Ahmed verfasserin aut Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 Mohamed, Khaled Abdel Hamid verfasserin aut Hussein, Ahmed Mohamed verfasserin aut Fouad, Mohamed Hassan verfasserin aut Allam, Ahmed Samir verfasserin aut Safwat, Eslam verfasserin aut Enthalten in Egyptian liver journal [London] : SpringerOpen, 2011 11(2021), 1 vom: 27. März (DE-627)1733559663 (DE-600)3038187-3 2090-6226 nnns volume:11 year:2021 number:1 day:27 month:03 https://dx.doi.org/10.1186/s43066-021-00090-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 11 2021 1 27 03 |
| spelling |
10.1186/s43066-021-00090-y doi (DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e DE-627 ger DE-627 rakwb eng Sakr, Marwa Ahmed verfasserin aut Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 Mohamed, Khaled Abdel Hamid verfasserin aut Hussein, Ahmed Mohamed verfasserin aut Fouad, Mohamed Hassan verfasserin aut Allam, Ahmed Samir verfasserin aut Safwat, Eslam verfasserin aut Enthalten in Egyptian liver journal [London] : SpringerOpen, 2011 11(2021), 1 vom: 27. März (DE-627)1733559663 (DE-600)3038187-3 2090-6226 nnns volume:11 year:2021 number:1 day:27 month:03 https://dx.doi.org/10.1186/s43066-021-00090-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 11 2021 1 27 03 |
| allfields_unstemmed |
10.1186/s43066-021-00090-y doi (DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e DE-627 ger DE-627 rakwb eng Sakr, Marwa Ahmed verfasserin aut Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 Mohamed, Khaled Abdel Hamid verfasserin aut Hussein, Ahmed Mohamed verfasserin aut Fouad, Mohamed Hassan verfasserin aut Allam, Ahmed Samir verfasserin aut Safwat, Eslam verfasserin aut Enthalten in Egyptian liver journal [London] : SpringerOpen, 2011 11(2021), 1 vom: 27. März (DE-627)1733559663 (DE-600)3038187-3 2090-6226 nnns volume:11 year:2021 number:1 day:27 month:03 https://dx.doi.org/10.1186/s43066-021-00090-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 11 2021 1 27 03 |
| allfieldsGer |
10.1186/s43066-021-00090-y doi (DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e DE-627 ger DE-627 rakwb eng Sakr, Marwa Ahmed verfasserin aut Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 Mohamed, Khaled Abdel Hamid verfasserin aut Hussein, Ahmed Mohamed verfasserin aut Fouad, Mohamed Hassan verfasserin aut Allam, Ahmed Samir verfasserin aut Safwat, Eslam verfasserin aut Enthalten in Egyptian liver journal [London] : SpringerOpen, 2011 11(2021), 1 vom: 27. März (DE-627)1733559663 (DE-600)3038187-3 2090-6226 nnns volume:11 year:2021 number:1 day:27 month:03 https://dx.doi.org/10.1186/s43066-021-00090-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 11 2021 1 27 03 |
| allfieldsSound |
10.1186/s43066-021-00090-y doi (DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e DE-627 ger DE-627 rakwb eng Sakr, Marwa Ahmed verfasserin aut Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy 2021 Text txt rdacontent Computermedien c rdamedia Online-Ressource cr rdacarrier Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 Mohamed, Khaled Abdel Hamid verfasserin aut Hussein, Ahmed Mohamed verfasserin aut Fouad, Mohamed Hassan verfasserin aut Allam, Ahmed Samir verfasserin aut Safwat, Eslam verfasserin aut Enthalten in Egyptian liver journal [London] : SpringerOpen, 2011 11(2021), 1 vom: 27. März (DE-627)1733559663 (DE-600)3038187-3 2090-6226 nnns volume:11 year:2021 number:1 day:27 month:03 https://dx.doi.org/10.1186/s43066-021-00090-y kostenfrei Volltext GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER AR 11 2021 1 27 03 |
| language |
English |
| source |
Enthalten in Egyptian liver journal 11(2021), 1 vom: 27. März volume:11 year:2021 number:1 day:27 month:03 |
| sourceStr |
Enthalten in Egyptian liver journal 11(2021), 1 vom: 27. März volume:11 year:2021 number:1 day:27 month:03 |
| format_phy_str_mv |
Article |
| institution |
findex.gbv.de |
| topic_facet |
HCC Soluble CD163 Transarterial chemoembolization Radiofrequency ablation |
| isfreeaccess_bool |
true |
| container_title |
Egyptian liver journal |
| authorswithroles_txt_mv |
Sakr, Marwa Ahmed @@aut@@ Mohamed, Khaled Abdel Hamid @@aut@@ Hussein, Ahmed Mohamed @@aut@@ Fouad, Mohamed Hassan @@aut@@ Allam, Ahmed Samir @@aut@@ Safwat, Eslam @@aut@@ |
| publishDateDaySort_date |
2021-03-27T00:00:00Z |
| hierarchy_top_id |
1733559663 |
| id |
SPR04364015X |
| language_de |
englisch |
| fullrecord |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR04364015X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210328064719.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210328s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43066-021-00090-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR04364015X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)SPRs43066-021-00090-y-e</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43066-021-00090-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sakr, Marwa Ahmed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HCC</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Soluble CD163</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Transarterial chemoembolization</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiofrequency ablation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohamed, Khaled Abdel Hamid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hussein, Ahmed Mohamed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fouad, Mohamed Hassan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allam, Ahmed Samir</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Safwat, Eslam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Egyptian liver journal</subfield><subfield code="d">[London] : SpringerOpen, 2011</subfield><subfield code="g">11(2021), 1 vom: 27. März</subfield><subfield code="w">(DE-627)1733559663</subfield><subfield code="w">(DE-600)3038187-3</subfield><subfield code="x">2090-6226</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">day:27</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43066-021-00090-y</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="b">27</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| author |
Sakr, Marwa Ahmed |
| spellingShingle |
Sakr, Marwa Ahmed misc HCC misc Soluble CD163 misc Transarterial chemoembolization misc Radiofrequency ablation Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| authorStr |
Sakr, Marwa Ahmed |
| ppnlink_with_tag_str_mv |
@@773@@(DE-627)1733559663 |
| format |
electronic Article |
| delete_txt_mv |
keep |
| author_role |
aut aut aut aut aut aut |
| collection |
springer |
| remote_str |
true |
| illustrated |
Not Illustrated |
| issn |
2090-6226 |
| topic_title |
Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy HCC (dpeaa)DE-He213 Soluble CD163 (dpeaa)DE-He213 Transarterial chemoembolization (dpeaa)DE-He213 Radiofrequency ablation (dpeaa)DE-He213 |
| topic |
misc HCC misc Soluble CD163 misc Transarterial chemoembolization misc Radiofrequency ablation |
| topic_unstemmed |
misc HCC misc Soluble CD163 misc Transarterial chemoembolization misc Radiofrequency ablation |
| topic_browse |
misc HCC misc Soluble CD163 misc Transarterial chemoembolization misc Radiofrequency ablation |
| format_facet |
Elektronische Aufsätze Aufsätze Elektronische Ressource |
| format_main_str_mv |
Text Zeitschrift/Artikel |
| carriertype_str_mv |
cr |
| hierarchy_parent_title |
Egyptian liver journal |
| hierarchy_parent_id |
1733559663 |
| hierarchy_top_title |
Egyptian liver journal |
| isfreeaccess_txt |
true |
| familylinks_str_mv |
(DE-627)1733559663 (DE-600)3038187-3 |
| title |
Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| ctrlnum |
(DE-627)SPR04364015X (DE-599)SPRs43066-021-00090-y-e (SPR)s43066-021-00090-y-e |
| title_full |
Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| author_sort |
Sakr, Marwa Ahmed |
| journal |
Egyptian liver journal |
| journalStr |
Egyptian liver journal |
| lang_code |
eng |
| isOA_bool |
true |
| recordtype |
marc |
| publishDateSort |
2021 |
| contenttype_str_mv |
txt |
| author_browse |
Sakr, Marwa Ahmed Mohamed, Khaled Abdel Hamid Hussein, Ahmed Mohamed Fouad, Mohamed Hassan Allam, Ahmed Samir Safwat, Eslam |
| container_volume |
11 |
| format_se |
Elektronische Aufsätze |
| author-letter |
Sakr, Marwa Ahmed |
| doi_str_mv |
10.1186/s43066-021-00090-y |
| author2-role |
verfasserin |
| title_sort |
diagnostic and prognostic value of serum soluble cd163 in cirrhotic patients with hepatitis c virus-related hepatocellular carcinoma before and after locoregional therapy |
| title_auth |
Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| abstract |
Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. |
| abstractGer |
Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. |
| abstract_unstemmed |
Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies. |
| collection_details |
GBV_USEFLAG_A SYSFLAG_A GBV_SPRINGER |
| container_issue |
1 |
| title_short |
Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy |
| url |
https://dx.doi.org/10.1186/s43066-021-00090-y |
| remote_bool |
true |
| author2 |
Mohamed, Khaled Abdel Hamid Hussein, Ahmed Mohamed Fouad, Mohamed Hassan Allam, Ahmed Samir Safwat, Eslam |
| author2Str |
Mohamed, Khaled Abdel Hamid Hussein, Ahmed Mohamed Fouad, Mohamed Hassan Allam, Ahmed Samir Safwat, Eslam |
| ppnlink |
1733559663 |
| mediatype_str_mv |
c |
| isOA_txt |
true |
| hochschulschrift_bool |
false |
| doi_str |
10.1186/s43066-021-00090-y |
| up_date |
2024-07-03T19:57:10.039Z |
| _version_ |
1803589129381871617 |
| fullrecord_marcxml |
<?xml version="1.0" encoding="UTF-8"?><collection xmlns="http://www.loc.gov/MARC21/slim"><record><leader>01000naa a22002652 4500</leader><controlfield tag="001">SPR04364015X</controlfield><controlfield tag="003">DE-627</controlfield><controlfield tag="005">20210328064719.0</controlfield><controlfield tag="007">cr uuu---uuuuu</controlfield><controlfield tag="008">210328s2021 xx |||||o 00| ||eng c</controlfield><datafield tag="024" ind1="7" ind2=" "><subfield code="a">10.1186/s43066-021-00090-y</subfield><subfield code="2">doi</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-627)SPR04364015X</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(DE-599)SPRs43066-021-00090-y-e</subfield></datafield><datafield tag="035" ind1=" " ind2=" "><subfield code="a">(SPR)s43066-021-00090-y-e</subfield></datafield><datafield tag="040" ind1=" " ind2=" "><subfield code="a">DE-627</subfield><subfield code="b">ger</subfield><subfield code="c">DE-627</subfield><subfield code="e">rakwb</subfield></datafield><datafield tag="041" ind1=" " ind2=" "><subfield code="a">eng</subfield></datafield><datafield tag="100" ind1="1" ind2=" "><subfield code="a">Sakr, Marwa Ahmed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="245" ind1="1" ind2="0"><subfield code="a">Diagnostic and prognostic value of serum soluble CD163 in cirrhotic patients with hepatitis C virus-related hepatocellular carcinoma before and after locoregional therapy</subfield></datafield><datafield tag="264" ind1=" " ind2="1"><subfield code="c">2021</subfield></datafield><datafield tag="336" ind1=" " ind2=" "><subfield code="a">Text</subfield><subfield code="b">txt</subfield><subfield code="2">rdacontent</subfield></datafield><datafield tag="337" ind1=" " ind2=" "><subfield code="a">Computermedien</subfield><subfield code="b">c</subfield><subfield code="2">rdamedia</subfield></datafield><datafield tag="338" ind1=" " ind2=" "><subfield code="a">Online-Ressource</subfield><subfield code="b">cr</subfield><subfield code="2">rdacarrier</subfield></datafield><datafield tag="520" ind1=" " ind2=" "><subfield code="a">Background Tumor-associated macrophages (TAMs), inflammatory cells in tumor microenvironment, are crucial for the tumor occurrence and progression which in turn increase the expression of soluble CD163 (sCD163). Nevertheless, not much has been established regarding sCD163 and its connection to HCC diagnosis and prognosis. This study was conducted to evaluate the diagnostic and prognostic role of sCD163 in patients with HCC on top of HCV-related liver cirrhosis. Forty adult patients with HCV-related liver cirrhosis and HCC (HCC group) were randomly selected and subjected to locoregional therapies, either transarterial chemoembolization (TACE) or radiofrequency ablation (RFA). Four patients were excluded because of portal vein invasion. Another group of 20 patients with liver cirrhosis only served as controls (LC group). Routine laboratory studies and abdominal ultrasound were done for all. Alpha-fetoprotein (AFP) and sCD163 were measured twice, at baseline and 1-month post-intervention, using a commercially available enzyme-linked immunosorbent assay kit. Results At baseline, sCD163 showed an insignificant higher value in HCC group (p > 0.05). The best cutoff value for sCD163 and AFP was 6.2 mg/L and 195 ng/mL, respectively. AFP had a larger area under the curve (0.88 vs. 0.767). An overall significant decline was seen in sCD163 after treatment (6.5±1.5 to 3.1±2.5 mg/L; p < 0.001), while AFP showed an insignificant decrease (p > 0.05). Also, sCD163 decreased significantly in the eradicated cases (6.1±1.4 mg/L before intervention vs. 2.3±1.4 mg/L after intervention, p < 0.01), while there was a significant increase in the recurrent cases (8.4±0.4 mg/L before intervention vs. 10.3±1.6 after intervention; p < 0.05). Moreover, sCD163 showed a significant difference in its pre-intervention and post-intervention values between recurrent and eradicated HCC cases (p < 0.01). Conclusions It is concluded that sCD163 has a minor role as a diagnostic marker for HCC, yet it could be used as a good prognostic marker in predicting the tumor response to locoregional therapies.</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">HCC</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Soluble CD163</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Transarterial chemoembolization</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="650" ind1=" " ind2="4"><subfield code="a">Radiofrequency ablation</subfield><subfield code="7">(dpeaa)DE-He213</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Mohamed, Khaled Abdel Hamid</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Hussein, Ahmed Mohamed</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Fouad, Mohamed Hassan</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Allam, Ahmed Samir</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="700" ind1="1" ind2=" "><subfield code="a">Safwat, Eslam</subfield><subfield code="e">verfasserin</subfield><subfield code="4">aut</subfield></datafield><datafield tag="773" ind1="0" ind2="8"><subfield code="i">Enthalten in</subfield><subfield code="t">Egyptian liver journal</subfield><subfield code="d">[London] : SpringerOpen, 2011</subfield><subfield code="g">11(2021), 1 vom: 27. März</subfield><subfield code="w">(DE-627)1733559663</subfield><subfield code="w">(DE-600)3038187-3</subfield><subfield code="x">2090-6226</subfield><subfield code="7">nnns</subfield></datafield><datafield tag="773" ind1="1" ind2="8"><subfield code="g">volume:11</subfield><subfield code="g">year:2021</subfield><subfield code="g">number:1</subfield><subfield code="g">day:27</subfield><subfield code="g">month:03</subfield></datafield><datafield tag="856" ind1="4" ind2="0"><subfield code="u">https://dx.doi.org/10.1186/s43066-021-00090-y</subfield><subfield code="z">kostenfrei</subfield><subfield code="3">Volltext</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_USEFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">SYSFLAG_A</subfield></datafield><datafield tag="912" ind1=" " ind2=" "><subfield code="a">GBV_SPRINGER</subfield></datafield><datafield tag="951" ind1=" " ind2=" "><subfield code="a">AR</subfield></datafield><datafield tag="952" ind1=" " ind2=" "><subfield code="d">11</subfield><subfield code="j">2021</subfield><subfield code="e">1</subfield><subfield code="b">27</subfield><subfield code="c">03</subfield></datafield></record></collection>
|
| score |
7.400941 |